Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nerve endings in the glans penis are microscopic anatomical structures comprising various types of sensory nerve terminals within the glans penis, the conical, distal expansion of the corpus spongiosum. The main types include free nerve endings (by far the most commonly observed), genital end bulbs, as well as small numbers of Pacinian and Ruffini corpuscles[1][4][5]. These nerve endings are present throughout all tissue layers, with a predominance of free nerve endings in nearly every dermal papilla. Genital end bulbs are most numerous in the corona and frenulum. The innervation is provided chiefly by the dorsal nerve of the penis (a branch of the pudendal nerve), and to a lesser extent by branches of the perineal nerve[1][2][4][8]. These nerve endings are responsible for the high tactile sensitivity of the glans penis, making it the principal sensory organ for sexual stimulation and pleasure in the male[1][3][5]. The transmitted somatosensory input is essential for sexual behaviors such as erection and ejaculation, with conduction primarily via the dorsal nerve. They are not a single molecular target or receptor but are rather a collection of anatomical/physiological structures composed of both myelinated and unmyelinated fibers, lacking specific ligand-binding or receptor function[7]. "Nerve endings in glans penis" is not considered a canonical molecular target, receptor, enzyme, transporter, or ion channel, but refers to heterogeneous sensory structures[4][1]. Individual molecular targets (such as specific sodium channels or receptors) may be found within these nerve endings; however, as a group, "nerve endings in glans penis" does not meet criteria for a druggable or pharmacologically targeted entity. No known approved drugs specifically target these collective nerve endings, nor are there recognized mechanisms of action or biomarkers related to their modulation as a unit. There are no known safety concerns, disease roles, or clinically targeted interventions specifically for these structures as a whole. However, the density and function of these nerve endings are implicated in sexual function, and their loss or damage (e.g., due to surgery, trauma, disease) may result in decreased sensitivity and sexual dysfunction[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nerve endings in glans penis.